|
Quotes & Info
|
| ISIS > SEC Filings for ISIS > Form 8-K on 11-Dec-2012 | All Recent SEC Filings |
11-Dec-2012
Entry into a Material Definitive Agreement, Financial Statements and Exh
On December 11, 2012, Isis Pharmaceuticals, Inc. ("Isis") and AstraZeneca announced that they have entered a strategic alliance agreement for the discovery and development of novel generation antisense therapeutics against five cancer targets, which includes a license to develop and commercialize ISIS-STAT3Rx, a drug Isis is currently evaluating in an early clinical trial in patients with advanced lymphomas.
Isis and AstraZeneca filed a press release describing this transaction. A copy of this press release is attached as Exhibit 99.1 to this Current Report and incorporated herein by reference.
(d) Exhibits.
99.1 Press Release dated December 11, 2012.
|
|